Intra-individual Variability of Serum Aldosterone and Implications for Primary Aldosteronism Screening

Nenhuma Miniatura disponível
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ENDOCRINE SOC
Autores
VILELA, Leticia A. P.
Citação
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.108, n.5, p.1143-1153, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Context Primary aldosteronism (PA) screening relies on an elevated aldosterone to renin ratio with a minimum aldosterone level, which varies from 10 to 15 ng/dL (277-415.5 pmol/L) using immunoassay. Objective To evaluate intra-individual coefficient of variation (CV) of aldosterone and aldosterone to direct renin concentration ratio (A/DRC) and its impact on PA screening. Methods A total of 671 aldosterone and DRC measurements were performed by the same chemiluminescence assays in a large cohort of 216 patients with confirmed PA and at least 2 screenings. Results The median intra-individual CV of aldosterone and A/DRC was 26.8% and 26.7%. Almost 40% of the patients had at least one aldosterone level <15 ng/dL, 19.9% had at least 2 aldosterone levels <15 ng/dL, and 16.2% had mean aldosterone levels <15 ng/dL. A lower cutoff of 10 ng/dL was associated with false negative rates for PA screening of 14.3% for a single aldosterone measurement, 4.6% for 2 aldosterone measurements, and only 2.3% for mean aldosterone levels. Considering the minimum aldosterone, true positive rate of aldosterone thresholds was 85.7% for 10 ng/dL and 61.6% for 15 ng/dL. An A/DRC >2 ng/dL/mu IU/mL had a true positive rate for PA diagnosis of 94.4% and 98.4% when based on 1 or 2 assessments, respectively. CV of aldosterone and A/DRC were not affected by sex, use of interfering antihypertensive medications, PA lateralization, hypokalemia, age, and number of hormone measurements. Conclusion Aldosterone concentrations had a high CV in PA patients, which results in an elevated rate of false negatives in a single screening for PA. Therefore, PA screening should be based on at least 2 screenings with concomitant aldosterone and renin measurements.
Palavras-chave
primary aldosteronism, aldosterone, renin, screening, variability
URI
https://observatorio.fm.usp.br/handle/OPI/54057
Referências
  1. Ahmed AH, 2011, J CLIN ENDOCR METAB, V96, P1797, DOI 10.1210/jc.2010-2918
  2. Almeida MQ, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-01106-5
  3. Amar L, 2016, ANN ENDOCRINOL-PARIS, V77, P179, DOI 10.1016/j.ando.2016.05.001
  4. Baudrand R, 2016, J CLIN ENDOCR METAB, V101, P3989, DOI 10.1210/jc.2016-1963
  5. Brown JM, 2020, ANN INTERN MED, V173, P10, DOI 10.7326/M20-0065
  6. Eisenhofer G, 2022, J CLIN ENDOCR METAB, V107, pE2027, DOI 10.1210/clinem/dgab924
  7. Funder JW, 2020, ANN INTERN MED, V173, P65, DOI 10.7326/M20-1758
  8. Funder JW, 2016, J CLIN ENDOCR METAB, V101, P1889, DOI 10.1210/jc.2015-4061
  9. Guo Z, 2018, J CLIN ENDOCR METAB, V103, P3965, DOI 10.1210/jc.2018-01041
  10. Hundemer GL, 2018, LANCET DIABETES ENDO, V6, P51, DOI 10.1016/S2213-8587(17)30367-4
  11. Lim V, 2014, J CLIN ENDOCR METAB, V99, P2712, DOI 10.1210/jc.2013-4146
  12. Monticone S, 2018, LANCET DIABETES ENDO, V6, P41, DOI 10.1016/S2213-8587(17)30319-4
  13. Monticone S, 2017, J AM COLL CARDIOL, V69, P1811, DOI 10.1016/j.jacc.2017.01.052
  14. Morera J, 2019, EUR J ENDOCRINOL, V180, pR45, DOI 10.1530/EJE-18-0704
  15. Mulatero P, 2004, J CLIN ENDOCR METAB, V89, P1045, DOI 10.1210/jc.2003-031337
  16. Nishikawa T, 2012, EXPERT REV ENDOCRINO, V7, P637, DOI [10.1586/eem.12.65, 10.1586/EEM.12.65]
  17. Rossi E, 2002, AM J HYPERTENS, V15, P896, DOI 10.1016/S0895-7061(02)02969-2
  18. Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059
  19. Rossi GP, 2016, CLIN CHEM LAB MED, V54, P1441, DOI 10.1515/cclm-2015-1094
  20. Rossi GP, 2015, J HYPERTENS, V33, P2546, DOI 10.1097/HJH.0000000000000748
  21. Rossi GP, 2014, HYPERTENSION, V63, P151, DOI 10.1161/HYPERTENSIONAHA.113.02097
  22. Barroso WKS, 2021, ARQ BRAS CARDIOL, V116, P516, DOI 10.36660/abc.20201238
  23. SIRAGY HM, 1995, J CLIN ENDOCR METAB, V80, P28, DOI 10.1210/jc.80.1.28
  24. [Anonymous], 2010, Arq. Bras. Cardiol., V95, pI
  25. Stowasser M, 2012, HORM METAB RES, V44, P170, DOI 10.1055/s-0031-1295460
  26. Tanabe A, 2003, J CLIN ENDOCR METAB, V88, P2489, DOI 10.1210/jc.2002-021476
  27. Thuzar M, 2020, J CLIN ENDOCR METAB, V105, pE477, DOI 10.1210/clinem/dgz150
  28. Vaidya A, 2018, ENDOCR REV, V39, P1057, DOI 10.1210/er.2018-00139
  29. VIEWEG WVR, 1992, AM J PHYSIOL, V262, pF871, DOI 10.1152/ajprenal.1992.262.5.F871
  30. Vilela LAP, 2019, J CLIN ENDOCR METAB, V104, P4695, DOI 10.1210/jc.2019-00531
  31. Vilela LAP, 2017, ARCH ENDOCRIN METAB, V61, P305, DOI 10.1590/2359-3997000000274
  32. Williams B, 2019, EUR HEART J, V40, P475, DOI 10.1093/eurheartj/ehy686
  33. Williams TA, 2017, LANCET DIABETES ENDO, V5, P689, DOI 10.1016/S2213-8587(17)30135-3
  34. Yozamp N, 2021, AM J HYPERTENS, V34, P34, DOI 10.1093/ajh/hpaa151
  35. Yozamp N, 2021, HYPERTENSION, V77, P891, DOI 10.1161/HYPERTENSIONAHA.120.16429
  36. Yozamp Nicholas, 2019, Curr Opin Endocr Metab Res, V8, P30, DOI 10.1016/j.coemr.2019.07.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Carregar mais